Artisan Partners' latest investor letter for the Artisan Small Cap Fund reveals its strategic adjustments amid evolving market conditions and legal concerns surrounding Ascendis Pharma (ASND).
In the second quarter of 2026, the Artisan Small Cap Fund reported notable performance, achieving returns that slightly surpassed the Russell 2000® Growth Index. This growth was attributed to robust U.S. economic indicators, such as steady growth, moderating inflation, and strong earnings, alongside ongoing investments in AI. Despite the positive overall performance, the fund faced challenges due to a market favoring high-leverage, loss-making companies, which complicated the landscape for quality-focused managers. Health care emerged as a significant contributor to performance, while sectors like technology and consumer discretionary negatively impacted returns.
Ascendis Pharma, a biopharmaceutical firm specializing in innovative therapies, was specifically mentioned in the letter. The company has seen a 52-week share price increase of 52.27%, despite a recent decline of 2.21% over the past month. Artisan Partners noted the potential of Ascendis but expressed caution, suggesting a reduction in their exposure to the stock amid ongoing lawsuit concerns.
This cautious approach reflects a broader strategy of selective investment as valuations rise and competitive risks become more pronounced. As the market evolves, the Artisan Small Cap Fund remains optimistic about small-cap opportunities, particularly in health care and AI infrastructure, while navigating the complexities of the current investment landscape.